Immune intervention reduces beta-cell death in type 1 diabetes

February 26, 2013
Immune intervention reduces beta-cell death in type 1 diabetes
Patients recently diagnosed with type 1 diabetes have greater death of pancreatic β-cells compared with patients with long-standing diabetes, which can be reduced by treatment with teplizumab, according to a study published online Feb. 19 in Diabetes.

(HealthDay)—Patients recently diagnosed with type 1 diabetes have greater death of pancreatic β-cells compared with patients with long-standing diabetes, which can be reduced by treatment with teplizumab, according to a study published online Feb. 19 in Diabetes.

Jasmin Lebastchi, from the Yale University School of Medicine in New Haven, Conn., and colleagues compared β- in 43 patients recently diagnosed with , 31 individuals without diabetes, and 37 patients with type 1 diabetes treated with teplizumab or placebo. β-cell death was determined by measuring relative levels of unmethylated INS DNA in serum.

The researchers found that, compared with individuals without diabetes, patients with recent-onset diabetes had higher rates of β-cell death, while patients with long-standing diabetes had lower levels of β-cell death. After treatment of recent-onset with teplizumab, β-cell death was significantly reduced and β-cell function was significantly better preserved.

"Improvement in C-peptide responses with immune intervention is associated with decreased β-cell death," Lebastchi and colleagues write.

Several authors have for teplizumab and/or the assay of unmethylated insulin DNA and are on the scientific advisory board of Islet Sciences.

Explore further: Worrying rise in alcohol related deaths among patients with diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Glucose levels at admission predict death in pneumonia

May 30, 2012

(HealthDay) -- For patients with community-acquired pneumonia without preexisting diabetes, serum glucose levels at admission are predictive of death at 28 and 90 days, according to a study published online May 29 in BMJ.

Turmeric component reduces type 2 diabetes incidence

July 12, 2012

(HealthDay) -- A component of turmeric -- curcumin -- reduces the incidence of type 2 diabetes and improves β-cell function in adults with prediabetes, according to a study published online July 6 in Diabetes Care.

Recommended for you

Electric fields weaker in slow-healing diabetic wounds

June 16, 2016

People with diabetes often suffer from wounds that are slow to heal and can lead to ulcers, gangrene and amputation. New research from an international group led by Min Zhao, professor of ophthalmology and of dermatology ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.